WO2012116196A3 - Substituted lactosyl compounds and use thereof for cellular imaging and therapy - Google Patents

Substituted lactosyl compounds and use thereof for cellular imaging and therapy Download PDF

Info

Publication number
WO2012116196A3
WO2012116196A3 PCT/US2012/026344 US2012026344W WO2012116196A3 WO 2012116196 A3 WO2012116196 A3 WO 2012116196A3 US 2012026344 W US2012026344 W US 2012026344W WO 2012116196 A3 WO2012116196 A3 WO 2012116196A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
lactosyl
substituted
therapy
cellular imaging
Prior art date
Application number
PCT/US2012/026344
Other languages
French (fr)
Other versions
WO2012116196A2 (en
Inventor
Nashaat TURKMAN
Ashutosh Pal
William B. TONG
Juri G. Gelovani
Mian M. Alauddin
Original Assignee
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents, The University Of Texas System filed Critical Board Of Regents, The University Of Texas System
Publication of WO2012116196A2 publication Critical patent/WO2012116196A2/en
Publication of WO2012116196A3 publication Critical patent/WO2012116196A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/005—Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention provides methods for producing compounds comprising a substitution at the 1'-position of a lactosyl ring. Also provided are compounds having a radionuclide, such as 18F substituted at the 1'-position of a lactosyl ring. Compounds according to the invention may be used as therapeutics or imaging agents, such as PET imaging agents. Methods for therapeutic and diagnostic use of substituted lactosyl compounds are also provided.
PCT/US2012/026344 2011-02-24 2012-02-23 Substituted lactosyl compounds and use thereof for cellular imaging and therapy WO2012116196A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161446183P 2011-02-24 2011-02-24
US61/446,183 2011-02-24

Publications (2)

Publication Number Publication Date
WO2012116196A2 WO2012116196A2 (en) 2012-08-30
WO2012116196A3 true WO2012116196A3 (en) 2012-11-22

Family

ID=46721455

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/026344 WO2012116196A2 (en) 2011-02-24 2012-02-23 Substituted lactosyl compounds and use thereof for cellular imaging and therapy

Country Status (1)

Country Link
WO (1) WO2012116196A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104817605B (en) * 2015-04-14 2017-09-08 湖北工程学院 2‑（The oxygen benzyl of 1 ', 2 ', 3 ' triazole 4 '）1,3,4,6 O acetyl group D glucose and its preparation method and application
CN104945456B (en) * 2015-06-04 2018-01-05 湖北工程学院 2‑（The Oxymethylene pyridine of 1 ', 2 ', 3 ' triazole 4 '）1,3,4,6 O acetyl group D glucose and its preparation method and application
CN104945457B (en) * 2015-06-10 2018-03-23 湖北工程学院 1‑（1 ', 3 ', 4 ', 6 '-four O acetyl group α/β D glucopyanosyls）4 contraposition substituted aryl [1,2,3] triazoles and its preparation method and application
WO2017019770A1 (en) * 2015-07-27 2017-02-02 Wayne State University Compositions and methods relating to galectin detection
TWI622679B (en) * 2016-04-29 2018-05-01 財團法人紡織產業綜合研究所 High frictional force fiber and method of fabricating the same
CN106366075B (en) * 2016-08-19 2018-06-12 北京市神经外科研究所 Pyrrolidines, salt, nuclear-magnetism probe and medicinal application, reagent, drug
CN116354830A (en) * 2017-05-19 2023-06-30 埃特纳科技有限公司 Process for the preparation of functionalized fluorinated monomers, fluorinated monomers and compositions for the preparation thereof
CN109232690A (en) * 2018-09-10 2019-01-18 南方医科大学南方医院 A kind of pet imaging agent standard items precursor and preparation method thereof
CN109369755B (en) * 2018-09-10 2022-03-04 南方医科大学南方医院 Positron imaging agent of targeting ASGPR (advanced persistent receptor-induced gpropy), and preparation method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090105184A1 (en) * 2007-09-19 2009-04-23 The Regents Of The University Of California Positron emission tomography probes for imaging immune activation and selected cancers
US20100111863A1 (en) * 2007-04-11 2010-05-06 Merck Eprova Ag 18f-labelled folates
US20100290988A1 (en) * 2009-05-15 2010-11-18 The Governors Of The University Of Alberta Fluorinated fructose derivatives for pet imaging
US20100322858A1 (en) * 2006-08-23 2010-12-23 Board Of Regents, The University Of Texas System Radiohaloimatinibs and Methods of Their Synthesis and Use in PET Imaging of Cancers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100322858A1 (en) * 2006-08-23 2010-12-23 Board Of Regents, The University Of Texas System Radiohaloimatinibs and Methods of Their Synthesis and Use in PET Imaging of Cancers
US20100111863A1 (en) * 2007-04-11 2010-05-06 Merck Eprova Ag 18f-labelled folates
US20090105184A1 (en) * 2007-09-19 2009-04-23 The Regents Of The University Of California Positron emission tomography probes for imaging immune activation and selected cancers
US20100290988A1 (en) * 2009-05-15 2010-11-18 The Governors Of The University Of Alberta Fluorinated fructose derivatives for pet imaging

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TURKMAN, N. ET AL.: "Radiosynthesis of 1-[18F]fluoroethyl-beta-D-lactose ([18F]-FEL) for early detection of pancreatic carcinomas with PET", JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 54, 25 March 2011 (2011-03-25), pages 232 - 238 *

Also Published As

Publication number Publication date
WO2012116196A2 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
WO2012116196A3 (en) Substituted lactosyl compounds and use thereof for cellular imaging and therapy
UA115122C2 (en) Cd3-binding molecules capable of binding to human and non-human cd3
WO2012065022A3 (en) Spiro-oxindole mdm2 antagonists
CL2014001752A1 (en) Substituted bicyclic compounds; pharmaceutical composition that includes them; and use in the treatment of diseases such as cancer, Alzheimer's, AIDS, among others.
WO2011060049A3 (en) Spiro-oxindole mdm2 antagonists
WO2012048099A3 (en) Nanoparticle-loaded cells
MX343135B (en) Fumagillol type compounds and methods of making and using same.
IN2012DN06629A (en)
MY158992A (en) Forms of rifaximin and uses thereof
PL2768937T3 (en) Formulations, their use as or for the manufacture of dishwashing agents and their manufacture
IL222897A (en) Compositions, compounds and methods for the synthesis and use of imaging agents
WO2011150156A3 (en) Heteroaryl compounds and methods of use thereof
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
ZA201401678B (en) Novel distributed 3,4-diamino-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
PL2968218T3 (en) Combination for the treatment of parkinson's disease
WO2012096929A3 (en) Heteroaryl compounds and methods of use thereof
MX347734B (en) S100a4 antibodies and therapeutic uses thereof.
AP2014007399A0 (en) Phenyl-3-AZA-bicycloÄ3.1.0Ühex-3-YL-methanones andthe use thereof as medicament
ZA201402907B (en) Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies
WO2013040227A3 (en) Therapeutic compounds
IL260078B (en) Therapy for use for the treatment of gaucher's disease
CL2014003123A1 (en) 5-amino [1,4], thiazines as bace1 inhibitors; use of the compound against Alzheimer's disease.
EP2946792A4 (en) THERAPEUTIC AGENT AND THERAPEUTIC METHOD RELATING TO 1,25D3-MARRS FOR NEUROLOGICAL DISEASE SUCH AS ALZHEIMER'S DISEASE& xA;
MX2018006226A (en) 5-hydroxytryptamine 1b receptor-stimulating agent for enhancing in vivo engraftment potential.
MX336369B (en) Use of ellagic acid as an anti-dandruff agent.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12748964

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12748964

Country of ref document: EP

Kind code of ref document: A2